Northwest Biotherapeutics Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc.

NWBO 0.232

-8.3%

Oct 29 3:58 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Area51

To: Area51 who wrote (750)	11/17/2020 3:00:50 PM
From: Gary Mohilner	1 Recommendation of 759

I believe it will move way up. If you look at the SNO presentation by Dr. Liau in 2018 I believe you'll see overall survival even then was excellent, Top 100 median near 60 months. At that time over the last 100 to enter the trial had not reached 60 months, those surviving will push the median up substantially, possibly beyond 72 months. The SAP which very probably delayed unblinding the trial, as the FDA took time to act, and perhaps wanted changes, is believed to now be accepted by all four regulators, the criteria is posted on European sites. This will make overall survival the key, not PFS which could have had problems by pseudoprogression being called progression. I believe approval will be a slam dunk. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next